Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European Society for Medical Oncology Congress 2026, while securing a new clinical oncology partnership with Incyte Corporation (NASDAQ:INCY).
Petosemtamab Shows Strong Survival In Head And Neck Cancer
In first-line recurrent or metastatic head and neck squamous cell carcinoma, Genmab on Monday presented updated Phase 2 data evaluating petosemtamab combined with pembrolizumab.
The regimen produced a median overall survival of 28.2 months and an overall response rate of 63%, with 19% of evaluable patients achieving a complete response.
Patients recorded a median progression-free survival of 9.0 months, while an estimated 55% of responders maintained their clinical response at 24 months.
Investigators observed consistent antitumor activity across PD-L1 expression levels and p16 subgroups. The study recorded no Grade 5 adverse events or treatment-related deaths.
Genmab continues to advance its global Phase 3 trial in this setting, anticipating topline data later this year.
Promising Response Rates In Metastatic Colorectal Cancer
Genmab on Sunday reported updated Phase 2 findings assessing petosemtamab alongside standard FOLFOX or FOLFIRI chemotherapy regimens in patients with metastatic colorectal cancer.
The combinations produced objective response rates of 75% in first-line treatment and 67% in second-line therapy, rising to 81% among first-line patients with left-sided tumors.
Subgroup analyses demonstrated robust activity in difficult-to-treat patients with liver metastases, generating response rates of 76% in first-line and 67% in second-line settings.
Disease control rates reached 95% and 93%, respectively.
Adverse events prompted treatment discontinuation in only 5% of mFOLFOX6 patients and 3% of FOLFIRI patients, while causing zero therapy-related fatalities.
Targeted Combination Partnership With Incyte
Expanding petosemtamab’s clinical reach, Genmab on Friday announced a clinical trial collaboration with Incyte to target first-line metastatic colorectal cancer bearing KRAS G12D mutations.
Under the agreement, Genmab will conduct a Phase 1/2 trial evaluating petosemtamab alongside standard chemotherapy and Incyte’s selective KRAS G12D candidate, INCB161734.
Incyte will co-fund the clinical study and provide investigational drug supplies.
GMAB Price Action: Genmab shares were up 1.56% at $44.93 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments